Argenx plans to submit supplemental BLA for efgartigimod in IMNM by end of 2026 after Phase 3 ALKIVIA shows 14.8-point TIS improvement

Argenx plans to submit a supplemental BLA for efgartigimod in immune-mediated necrotizing myopathy (IMNM) by end of 2026, after Phase 3 ALKIVIA showed a 14.8-point greater TIS improvement versus placebo at week 52.

Detected & updated continuously · Source: Nebula